 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H22N2O |
| Molar mass | 246.354 g·mol−1 |
| 3D model (JSmol) | |
| |
Piquindone (Ro 22-1319) is anatypical antipsychotic with atricyclicstructure that was developed in the 1980s but was never marketed.[1][2][3] It acts as aselectiveD2 receptorantagonist,[4][5][6] though based on its effects profile its selectivity may be considered controversial. Unlike most other D2 receptor ligands, piquindone displaysNa+-dependentbinding, a property it shares withtropapride,zetidoline, andmetoclopramide.[7]
Inclinical trials piquindone was found to possess moderate efficacy in treatingpositive symptoms of schizophrenia, and notably, was also modestly effective fornegative symptoms, though this was just under statistical significance.[1] Additionally, relative tohaloperidol, it was found to possesses significantly fewerextrapyramidal symptoms and had a much lower propensity for inducingtardive dyskinesia, indicating itsatypical nature.[1][3] In addition topsychosis, piquindone has also been found to be effective in the treatment ofTourette's syndrome in numerous clinical studies.[8][9][10][11]
